Novel therapy for children with chronic hormone deficiency provides lifeline for parents
- Alkindi® is the first replacement therapy specially designed for infants, children and adolescents with paediatric adrenal insufficiency
- Adrenal insufficiency is caused by a lack of the stress hormone cortisol – which can be fatal
- This new therapy, which has been developed by University of Sheffield spin-out company Diurnal, has been granted market authorisation by the European Medicine Agency.
Recent Blog Posts
Article: Adult Quality of Life with CAH
A new study published in Endocrine Connections explores the lived experiences of adults with congenital adrenal hyperplasia (CAH) and the wide-ranging impact the condition can have on quality of life. Through in-depth interviews with adults living with CAH as well as...
Liquid Hydrocortisone Discontinued in the UK
Liquid hydrocortisone injections have been discontinued in the UK, affecting emergency treatment for people with adrenal insufficiency. This follows the supply shortage reported in February 2025 -...
Medicine security – a national UK priority.
Concerns about medicines shortages in the UK have been highlighted in recent analysis from the House of Lords Public Services Committee and the Royal Pharmaceutical Society. The House of Lords Public Services Committee warns that medicines supply should be treated as...